Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin C in G6PDA and PKD
NCT07612345Phase 1Not yet recruiting
- Sponsor
- University of Utah
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ascorbic acid in pyruvate kinase deficiency (PKD) and glucose-6-phosphate dehydrogenase deficiency (3 arms), sponsored by University of Utah. Primary endpoints: Incidence of Dose-Limiting Toxicities at 7 weeks, Number of Participants With Treatment-Related Adverse Events at 7 weeks and 5 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ascorbic acid
03
Conditions
pyruvate kinase deficiency (PKD)glucose-6-phosphate dehydrogenase deficiency
Beyond the preview
Go deeper on NCT07612345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612345.